Operating Income: The income after operating expenses.
Cullinan Therapeutics, Inc. (CGEM) had Operating Income of $-53.70M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-49.66M |
|
-- |
|
-- |
|
$53.70M |
|
|
Operating Income |
$-53.70M |
$4.04M |
|
$-49.66M |
|
$-49.66M |
|
$-49.66M |
|
$-49.66M |
|
$-49.66M |
|
$-49.66M |
|
$-53.70M |
|
$-53.62M |
|
60.46M |
|
60.46M |
|
$-0.75 |
|
$-0.75 |
|
| Balance Sheet Financials | |
$361.41M |
|
$0.34M |
|
$41.58M |
|
$402.98M |
|
$35.15M |
|
-- |
|
$1.66M |
|
$36.81M |
|
$366.17M |
|
$366.17M |
|
$366.17M |
|
61.45M |
|
| Cash Flow Statement Financials | |
$-46.05M |
|
$32.41M |
|
$0.38M |
|
$88.33M |
|
$75.08M |
|
$-13.25M |
|
$7.62M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.28 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-46.05M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-13.56% |
|
-13.56% |
|
-12.32% |
|
-13.56% |
|
$5.96 |
|
$-0.76 |
|
$-0.76 |
|